The U.S. Food and Drug Administration (FDA) announced a December 13 meeting of outside medical experts who will consider new data on the increased risk of "suicidality" (suicidal thinking and behavior) in young adults taking antidepressant medications. This meeting is a follow-up to two meetings on antidepressants and suicidality in pediatric patients held in February and September, 2004.
The FDA states that it plans to modify antidepressant drug labels based on the panel's findings.